A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy

Trial Profile

A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs AZD 3241 (Primary)
  • Indications Multiple system atrophy
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Mar 2018 Data from one phase I study (NCT00914303) and one phase II study in Multiple System Atrophy (NCT02388295) trial was used to develop PopPK model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 25 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top